24 Sep 2025
INCA SCAN 2025 Survey
According to the Survey of Challenges in Access to Diagnostics and Treatment for NET Patients (SCAN 2019), globally, it takes 5 years on average from initial symptoms of a neuroendocrine tumour to actual diagnosis. The SCAN 2019 survey, which some of you may have completed, represents the biggest global compendium of neuroendocrine tumour data.
This year, INCA is launching the SCAN 2025 Global Survey to compare the results on the same key measurements from 2019 and map the status of diagnostics, treatments and care for neuroendocrine tumours from the point of view of patients and healthcare professionals.
If you have had any of the following neuroendocrine tumours alone or within your genetic syndrome, please have your say and participate in the survey: medullary thyroid cancer, phaeochromocytoma, paraganglioma, duodenopancreatic tumour.
The SCAN 2025 Global Survey and the campaign messages are available in 15 languages. You can find out more information on SCAN 2019 and 2025, as well as assets for raising awareness on social media on the INCA website.
.